Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold common stock totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• On November 6, 2025, 4,000 stock options were exercised at $120.26 per share, and 4,000 shares of common stock were sold at weighted average prices of $448.1387 and $449.4421.
• On November 7, 2025, an additional 4,000 stock options were exercised at $120.26 per share, and 4,000 shares of common stock were sold at weighted average prices of $446.4239, $448.04, and $452.21.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• Following these transactions, direct beneficial ownership of common stock is 130 shares, with indirect ownership totaling 644,359 shares through a spouse and various family trusts.
• The reporting person holds 114,000 remaining stock options with an exercise price of $120.26 and an expiration date of March 15, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, the transactions are part of a pre-arranged 10b5-1 plan, which mitigates concerns about reactive selling. The high sale prices relative to the exercise price indicate a profitable transaction for the insider, and significant indirect ownership is retained.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The sale prices for the common stock were significantly higher than the exercise price of the options, indicating a substantial gain for the reporting person.
• The reporting person retains significant indirect beneficial ownership through family trusts, totaling 644,359 shares.

Negatives

• The transactions represent insider selling, which can sometimes be perceived negatively by the market, even if pre-planned.
• The direct beneficial ownership of common stock by the CEO was reduced to 130 shares after these transactions.

Risks

• No specific risks are mentioned in this Form 4 filing, as it primarily reports transactions. General market risks for UTHR stock apply.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the continuation of the pre-arranged 10b5-1 trading plan until its specified end date or option exhaustion.

Industry Context

This Form 4 filing reports routine insider transactions under a pre-arranged plan and does not provide information directly related to broader industry trends or competitive landscape for United Therapeutics Corp.

Comparison to Industry Standards

• Not applicable. This filing reports insider trading activity, which is not typically compared to industry standards in terms of performance or operational benchmarks. The execution of a 10b5-1 plan is a standard practice for insiders to manage their equity holdings.

Related Party Transactions

• Shares are held indirectly by a spouse and various family trusts, as to which the Reporting Person or their spouse share investment power or are beneficiaries/trustees. These represent related party holdings.

Stakeholder Impact

• Shareholders may observe the insider selling, which could lead to varied interpretations, though the 10b5-1 plan context typically reduces negative sentiment.
• The transactions demonstrate the Chairperson & CEO's monetization of long-held equity compensation.

Next Steps

• The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options (expiring March 15, 2026) or December 31, 2025.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which is a common practice for executives to diversify their holdings and manage tax liabilities. While it involves selling shares, the pre-planned nature and the significant remaining indirect beneficial ownership suggest it's not a signal of a negative outlook on the company's future. Therefore, a 'hold' recommendation is appropriate, as this specific filing does not present new fundamental information to warrant a change in investment thesis, but rather reflects a planned personal financial action.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Beneficial Ownership